Logo image of CNTX

CONTEXT THERAPEUTICS INC (CNTX) Stock Fundamental Analysis

NASDAQ:CNTX - Nasdaq - US21077P1084 - Common Stock - Currency: USD

0.699  0 (0%)

After market: 0.7129 +0.01 (+1.99%)

Fundamental Rating

3

Taking everything into account, CNTX scores 3 out of 10 in our fundamental rating. CNTX was compared to 193 industry peers in the Pharmaceuticals industry. CNTX has a great financial health rating, but its profitability evaluates not so good. CNTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CNTX had negative earnings in the past year.
In the past year CNTX has reported a negative cash flow from operations.
In the past 5 years CNTX reported 4 times negative net income.
CNTX had a negative operating cash flow in each of the past 5 years.
CNTX Yearly Net Income VS EBIT VS OCF VS FCFCNTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

CNTX has a Return On Assets (-29.73%) which is comparable to the rest of the industry.
CNTX has a better Return On Equity (-30.37%) than 63.21% of its industry peers.
Industry RankSector Rank
ROA -29.73%
ROE -30.37%
ROIC N/A
ROA(3y)-71.84%
ROA(5y)235.37%
ROE(3y)-90.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNTX Yearly ROA, ROE, ROICCNTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

1.3 Margins

CNTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNTX Yearly Profit, Operating, Gross MarginsCNTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

CNTX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CNTX has been increased compared to 5 years ago.
There is no outstanding debt for CNTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CNTX Yearly Shares OutstandingCNTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CNTX Yearly Total Debt VS Total AssetsCNTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

CNTX has an Altman-Z score of 17.53. This indicates that CNTX is financially healthy and has little risk of bankruptcy at the moment.
CNTX's Altman-Z score of 17.53 is amongst the best of the industry. CNTX outperforms 90.16% of its industry peers.
There is no outstanding debt for CNTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 17.53
ROIC/WACCN/A
WACCN/A
CNTX Yearly LT Debt VS Equity VS FCFCNTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

CNTX has a Current Ratio of 48.80. This indicates that CNTX is financially healthy and has no problem in meeting its short term obligations.
CNTX has a Current ratio of 48.80. This is amongst the best in the industry. CNTX outperforms 99.48% of its industry peers.
CNTX has a Quick Ratio of 48.80. This indicates that CNTX is financially healthy and has no problem in meeting its short term obligations.
CNTX has a Quick ratio of 48.80. This is amongst the best in the industry. CNTX outperforms 99.48% of its industry peers.
Industry RankSector Rank
Current Ratio 48.8
Quick Ratio 48.8
CNTX Yearly Current Assets VS Current LiabilitesCNTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 62.26% over the past year.
EPS 1Y (TTM)62.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-125%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CNTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.12% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y53%
EPS Next 2Y17.81%
EPS Next 3Y9.34%
EPS Next 5Y14.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CNTX Yearly Revenue VS EstimatesCNTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M
CNTX Yearly EPS VS EstimatesCNTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CNTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CNTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNTX Price Earnings VS Forward Price EarningsCNTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNTX Per share dataCNTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.81%
EPS Next 3Y9.34%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CNTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CONTEXT THERAPEUTICS INC

NASDAQ:CNTX (8/7/2025, 8:18:22 PM)

After market: 0.7129 +0.01 (+1.99%)

0.699

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)N/A N/A
Inst Owners79.94%
Inst Owner ChangeN/A
Ins Owners1.21%
Ins Owner Change16.17%
Market Cap62.70M
Analysts83.33
Price Target6.29 (799.86%)
Short Float %1.81%
Short Ratio6.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.47%
Min EPS beat(2)15.19%
Max EPS beat(2)57.74%
EPS beat(4)3
Avg EPS beat(4)3.81%
Min EPS beat(4)-105.41%
Max EPS beat(4)57.74%
EPS beat(8)4
Avg EPS beat(8)-2.83%
EPS beat(12)7
Avg EPS beat(12)-7.86%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.57%
PT rev (3m)-1.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.97%
EPS NY rev (1m)0.43%
EPS NY rev (3m)9.69%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.69
P/tB 0.69
EV/EBITDA N/A
EPS(TTM)-0.4
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0
BVpS1.01
TBVpS1.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.73%
ROE -30.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-71.84%
ROA(5y)235.37%
ROE(3y)-90.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 48.8
Quick Ratio 48.8
Altman-Z 17.53
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)155.66%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-125%
EPS Next Y53%
EPS Next 2Y17.81%
EPS Next 3Y9.34%
EPS Next 5Y14.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-42.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.53%
OCF growth 3YN/A
OCF growth 5YN/A